DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based ...

Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. Rates of first NGS relative to the time of death (in pts ...

“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...

A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK fusion mutation and treat him with targeted therapy instead of chemotherapy.

Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC Thermo ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...